Business Context and Reporting Period
Company: Praxis Precision Medicines, Inc. (PRAX)
Filing Type: Form 8-K (Current Report)
Date of Report: January 6, 2026
Reporting Period: As of December 31, 2025 (Preliminary Unaudited)
Key Financial Metrics
The filing provides preliminary, unaudited liquidity data only. Comprehensive financial results are not included.
- Cash, Cash Equivalents, and Marketable Securities: Approximately $925 million as of December 31, 2025.
- Revenue, Profit, and Margins: Not provided in this filing.
- Debt and Liquidity: Only cash position is disclosed; debt levels are not specified.
Material Changes
This report does not contain comparative data against prior periods. The disclosed cash balance represents a preliminary estimate for the year ended December 31, 2025, and is subject to adjustment upon completion of financial closing procedures.
Guidance, Outlook, and Risks
Management Commentary: The financial information is based on management estimates and is not a comprehensive statement of financial results. The independent registered public accounting firm has not audited or reviewed these figures.
Risks and Contingencies:
- The data is subject to potential adjustments resulting from financial closing procedures and the upcoming audit.
- Forward-looking statements are subject to risks and uncertainties described in the Company's Form 10-K for 2024 and Form 10-Q for the quarter ended June 30, 2025.
- The Company undertakes no obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the final audited cash, cash equivalents, and marketable securities balance in the upcoming Form 10-K for the year ended December 31, 2025.
- Review the Form 10-K for 2024 and Form 10-Q for the quarter ended June 30, 2025 for detailed risk factors and historical financial performance.
- Confirm whether the preliminary $925 million estimate requires material adjustment after the independent audit is completed.